Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa Therapeutics (GLUE.O), opens new tab $150 million upfront payment for a global license to develop ...

Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...

"Building on the longstanding experience of Novartis in nephrology and our first rare kidney disease approval in IgA nephropathy earlier this year, these results in C3G show continued advancement ...

Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...

Switzerland-based Novartis has an Earnings ESP of +1.51% and carries a Zacks Rank #2. The Zacks Consensus Estimate for the third quarter is pegged at earnings of $1.94 per share. Novartis is set ...

Credit: Tada Images via Shutterstock. Intercept Pharmaceuticals will have to keep waiting for a decision about Ocaliva (obeticholic acid) after the US Food and Drug Administration (FDA) has asked for ...

A pharmaceutical body has warned of potential shortages of some medicines in Northern Ireland unless there is a delay to the implementation of the Windsor Framework. The framework is the post ...

“This agreement with Novartis marks a pivotal moment for 3BP,” said Ulrich Reineke, Managing Director of 3B Pharmaceuticals. “If the option for the asset purchase is exercised, we are confident that ...